Summary of Via Biotechnology Conference Call Company Overview - **Company**: Via Biotechnology - **Industry**: Biotechnology and Pharmaceutical Development Key Points and Arguments AI-Driven Drug Design - Via Biotechnology utilizes an AI drug expert model that combines protein and chemical large language models to enhance structure-based drug design capabilities, particularly in understanding protein-small molecule interactions, significantly accelerating lead compound discovery and optimization [2][3] - The AI-driven drug design process allows for modeling and molecular generation that considers multiple properties such as activity and ADMET, reducing the R&D cycle time by 2-3 times and cutting costs by approximately 50%, outperforming traditional drug design methods [2][6] Antibody Discovery Efficiency - The AI-driven antibody discovery process can complete sequence design in less than a week, reducing the number of tests by 10^7 to 10^8 times and shortening experimental validation periods to 2-3 weeks, thus significantly improving efficiency and data quality [2][7] AI Drug Design Platform - The AI-driven drug design platform includes three modules: V-Sector, V-Orb, and V-Mental, which provide foundational computational chemistry tools, principles of molecular interactions, and generative AI models, respectively. This platform enhances R&D efficiency by 400% with a success rate exceeding 85% [2][8] PCSK9 Molecule Development - Via Biotechnology designed the PCSK9 molecule, which is currently in clinical phase II development by AstraZeneca. Results indicate that patients' low-density lipoprotein levels reached target ranges, with ADMET data showing an accuracy exceeding 80% compared to platform predictions, validating the AI algorithm's early-stage application value in drug development [2][9] CDMO Business Growth - The CDMO (Contract Development and Manufacturing Organization) business is progressing steadily, with multiple projects on track for commercialization by the end of 2025 and 2026. Current project capacity utilization has reached over 70%, contributing significantly to revenue and profit growth [4][23][24] Competitive Landscape and Advantages - In the AI pharmaceutical sector, Via Biotechnology's main advantage lies in its deep understanding of mechanisms and a comprehensive platform, which is crucial for integrating drug design and computational technology. The company emphasizes the importance of collaboration and communication among teams to enhance research and development [18][19] Geopolitical Factors - The impact of U.S.-China relations and geopolitical factors on Via Biotechnology's business is currently unclear, though potential tariff changes could affect operations. However, the company has not observed significant shifts in customer behavior due to political tensions [20][21] AI's Impact on Business Growth - AI is increasingly recognized for its value in drug development, with many pharmaceutical companies exploring AI-driven methods. The integration of AI is expected to save time and costs while enhancing project outcomes, leading to significant business growth for Via Biotechnology [22] Project and Client Development - Via Biotechnology is actively pursuing new clients in the CDMO sector, with ongoing discussions with major pharmaceutical companies in Europe to explore commercialization opportunities [27] Overall Business Development - The company is experiencing positive developments across its various business segments, with a strong focus on integrating AI technology to drive further growth and innovation [28]

Core Viewpoint - Jingtai Holdings (02228.HK) is expanding its AI medical footprint by acquiring 90% of Shanghai Siwei Medical Technology Co., Ltd. for a transaction price of 250 million yuan, marking a significant step in its AI healthcare strategy [1][2]. Group 1: Acquisition Details - The acquisition price will be settled entirely in cash, with Siwei Medical projected to generate revenues of 39.61 million yuan and a net profit of 5.25 million yuan for the fiscal year ending December 31, 2024 [1]. - The acquisition values Siwei Medical at a price-to-sales ratio of 7.0 times and a price-to-earnings ratio of 52.9 times [1]. - The board of Jingtai Holdings believes the transaction price is fair and reasonable, aligning with comparable data from five similar listed companies [1]. Group 2: Performance Commitments - The seller and guarantor have committed that Siwei Medical's main business revenue from projects in Shanghai will not be less than 27 million yuan for the fiscal year ending December 31, 2025, indicating a focus on business stability in a specific region [2]. Group 3: Company Background - Siwei Medical, established in 2008, is a high-tech enterprise and the largest provider of remote ECG diagnostic services in China, also involved in AI remote diagnostic innovations [2]. - Jingtai Holdings, founded in 2015 by three MIT physicists, has been deeply engaged in the AI pharmaceutical sector and went public on the Hong Kong Stock Exchange in June 2024 [2]. Group 4: Financial Performance - Jingtai Holdings has reported losses for five consecutive years, with cumulative losses reaching 7.741 billion yuan from 2020 to 2024 [2]. - The company's net losses for the years 2020 to 2024 were 734 million yuan, 2.137 billion yuan, 1.439 billion yuan, 1.914 billion yuan, and 1.517 billion yuan, respectively [2]. Group 5: Stock Performance - Since its listing, Jingtai Holdings' stock price has experienced significant volatility, with a dramatic decline of 74% from September 10 to November 19, 2024 [3]. - As of May 12, 2025, the stock price increased by 3.24%, closing at 4.78 HKD per share [3].

Group 1 - AI pharmaceutical company Insilico Medicine has filed for an IPO on the Hong Kong Stock Exchange, marking its third attempt after previous submissions in June 2023 and March 2024 failed [2] - The IPO aims to raise funds primarily for clinical development of pipeline candidates, development of new generative AI models, expansion of automated laboratories, and operational funding [2] Group 2 - Chasing Technology, established in 2017, has rapidly transformed into a major player in the smart cleaning market, leveraging its proprietary high-speed digital motor and intelligent algorithms [3] - The company has achieved a retail market share of 16.2% in China's cleaning appliance market for 2024, ranking first [3] - During the 2024 Double Eleven shopping festival, Chasing Technology's total GMV exceeded 3.2 billion yuan, topping the sales charts across major platforms [3] Group 3 - Porsche is undergoing a planned and rapid restructuring of its board, focusing on product strategy and generational change in governance to establish a younger and more stable management team [4] - Wanda Film announced a new round of investment in 52TOYS, with the company being valued at over 4 billion yuan [4] - Zhongqi Cloud Chain has submitted a listing application to the Hong Kong Stock Exchange, with several financial institutions acting as joint sponsors [5] - Xunzhong Communication has also filed for an IPO on the Hong Kong Stock Exchange, marking its second attempt after a previous application was halted [5] - Zhixing Technology's subsidiary has signed a framework agreement to acquire a majority stake in Xiaogongjian Robot, becoming its controlling shareholder [5] - Deyi Group has submitted its application to the Hong Kong Stock Exchange, claiming a leading position in the gamma radiation surgical equipment market in China [6]

Core Viewpoint - Insilico Medicine's third attempt to list on the Hong Kong Stock Exchange is crucial not only for its future development but also for the AI pharmaceutical sector to achieve reasonable market valuation and favor [1] Business Model - Insilico Medicine operates in three main segments: drug discovery and pipeline development, software solutions, and other discoveries related to non-pharmaceutical fields [2] - The pipeline drug development includes commercialization of self-developed pipelines post-approval, revenue from licensing candidate drugs, and income from drug discovery collaborations. Currently, the company has no commercialized candidate drugs, with revenue primarily from three licensed candidate drugs [2] - The company utilizes its Pharma.AI platform for drug discovery, charging clients subscription fees for access, with the highest annual subscription fee for hosted software at $200,000 and for local software at $525,000 [2] Financial Performance - Revenue has shown consistent growth from $30.15 million in 2022 to $51.18 million in 2023, and projected to reach $85.83 million in 2024, with a compound annual growth rate (CAGR) of 69% from 2022 to 2024 [4] - Gross margins have improved significantly, rising from 63.4% in 2022 to 90.4% in 2024, with net losses narrowing by nearly 92% over the same period [4][5] - The company reported a net cash outflow from operating activities of $57.4 million in 2024, relying on financing to support R&D [9] Industry Growth - The global AI pharmaceutical market is expected to exceed $5 billion by 2025, with a CAGR of 40%. The market for lung fibrosis drugs is projected to grow at a CAGR of 7.1% from 2023 to 2032 [13] Competitive Landscape - Insilico Medicine differentiates itself through its end-to-end platform, with significant advantages in target discovery, molecular generation, and clinical trials compared to international peers [15] - The company operates under the AI+Biotech model, focusing on self-developed pipelines and covering the entire drug development chain [15] Advantages - The company has a strong technical foundation, with one of its assets in the II clinical phase being the fastest progressing in its field. The Pharma.AI platform significantly reduces drug development timelines [17] - Insilico Medicine has established international collaborations, validating its commercialization capabilities, including exclusive licensing agreements with Exelixis Inc and Stemline Therapeutics Inc [18] R&D Expenditure - R&D expenses have been gradually controlled, with the proportion of R&D costs to revenue decreasing from 259% in 2022 to 107% in 2024 [19] Client and Supplier Concentration - The company has a high concentration of revenue from its top five clients, accounting for 90.6% to 94.4% of total revenue from 2022 to 2024 [22]

Core Insights - The rise of AI technology, particularly generative AI, is expected to significantly enhance the efficiency of drug development processes, including target identification, drug discovery, and clinical research [1] - The global AI pharmaceutical market is experiencing rapid growth, with an estimated market size of $1.04 billion in 2022, projected to reach nearly $3 billion by 2026, and expected to exceed $20 billion by 2032 [13][14] Company Overview - Insilico Medicine, founded in 2014, is an AI-driven biotechnology company that has attracted significant investment, raising over $500 million to date, with a valuation of $1.33 billion as of early 2023 [2][10] - The company has a unique "dual CEO" structure, balancing AI development and drug discovery, with its current clinical asset being one of the most advanced in the industry [5][6] IPO Progress - Insilico Medicine is making its third attempt to go public on the Hong Kong Stock Exchange, with its IPO process ongoing for nearly two years [2][7] - The funds raised from the IPO will primarily support clinical development of pipeline candidates, AI model development, and operational expenses [8] Financial Performance - Insilico Medicine has not yet commercialized its candidate drugs, reporting revenues of approximately $30.15 million, $51.18 million, and $85.83 million from 2022 to 2024, with net losses exceeding $300 million over the same period [9][10] - Despite ongoing losses, the company has maintained strong market interest and investment, reflecting confidence in its AI-driven drug development capabilities [9][10] Market Dynamics - The AI drug discovery market is rapidly expanding, with significant investments from both venture capital and traditional pharmaceutical companies, indicating a robust interest in AI applications in drug development [14][15] - In China, the AI pharmaceutical market is projected to grow from 8.16 million yuan in 2020 to 77.4 million yuan by 2025, with a compound annual growth rate of 56.8% [14] Future Outlook - Experts believe that AI is transitioning from a supportive tool to a core engine in drug development, with the potential to reshape the pharmaceutical industry and create substantial market growth in the coming decade [17]

Core Viewpoint - The AI pharmaceutical sector is becoming a new high ground for global capital competition, with companies like Insilico Medicine facing commercialization challenges despite significant interest from investors [1][7]. Group 1: Company Overview - Insilico Medicine has submitted its IPO application to the Hong Kong Stock Exchange for the third time, reflecting its ongoing struggle to achieve commercialization [4][5]. - The company, founded in 2014, has developed a generative AI platform, Pharma.AI, which has produced over 20 clinical or IND-stage assets, with three assets licensed to international pharmaceutical companies valued at over $2 billion [4][5]. - Insilico Medicine has raised over $100 million in its E-round financing in February 2025, with a post-money valuation of approximately $1.331 billion [5]. Group 2: Financial Performance - Insilico Medicine has reported continuous losses, with revenues of $30.147 million, $51.18 million, and $85.834 million from 2022 to 2024, while losses narrowed from $222 million to $17.096 million during the same period [7][8]. - The company's cash and cash equivalents have decreased from $208 million in 2022 to $126 million in 2024, while its net debt has increased from $450 million to $664 million [10][11]. Group 3: Market Dynamics - The global market for AI-enabled drug development is projected to grow from $11.9 billion in 2023 to $74.6 billion by 2032, with a compound annual growth rate (CAGR) of 22.6% [4]. - Insilico Medicine's revenue primarily comes from licensing agreements, with collaborations increasing from 42 clients in 2022 to 59 in 2024 [8]. Group 4: Challenges and Future Outlook - The company faces significant commercialization challenges, with its candidate drugs not yet commercialized and ongoing high R&D expenditures leading to negative cash flow [7][10]. - The AI pharmaceutical industry is still grappling with uncertainties regarding its development pathways, particularly in distinguishing between contract research organization (CRO) and pipeline development [7][9]. - Insilico Medicine's future success in the IPO process could have profound implications for the AI pharmaceutical sector in China [11].

Core Viewpoint - In its third attempt to go public, the company InSilico Medicine has submitted an updated prospectus to the Hong Kong Stock Exchange, following two previous unsuccessful applications due to not passing hearings within the six-month validity period [1] Financial Performance - Revenue increased from $30.147 million in 2022 to $85.834 million in 2024, with a gross profit margin rising from 63.4% to 90.4% [2][4] - The company reported net losses of $221.828 million in 2022, $211.640 million in 2023, and an expected loss of $17.096 million in 2024, indicating a narrowing loss primarily due to controlled R&D expenses and increased licensing income [4] Product Development and Pipeline - InSilico Medicine's core competitive advantage lies in its proprietary AI platform, Pharma.AI, which has generated over 20 clinical or IND-stage assets, with 10 receiving clinical trial approvals and 3 licensed to international pharmaceutical companies, totaling over $2 billion in contract value [3] - The lead product, ISM001-055, a selective TNIK small molecule inhibitor, has received orphan drug designation from the FDA and is expected to submit IND applications for kidney fibrosis and IPF treatments in 2025 [3][4] Market Position and Industry Context - InSilico Medicine aims to become the second AI pharmaceutical company listed on the Hong Kong Stock Exchange, following the successful listing of another company, Crystal Bio, which has been viewed as the first AI pharmaceutical stock [4] - The company operates on an AI + biotech model, focusing on self-developed pipeline licensing, with over 90% of its revenue coming from licensing in 2024 [5] Challenges and Risks - The company faces challenges related to data quality, as the external biomedical data used by Pharma.AI may be incomplete or inconsistent, potentially affecting model prediction accuracy [5] - There is significant uncertainty in clinical phases, particularly in the IIb and III phases, where failure rates are high, especially in the IPF treatment area [5][6]

证券代码：300583 证券简称：赛托生物 山东赛托生物科技股份有限公司 投资者关系活动记录表 编号：DY2025-001 投资者关系活 动类别 □特定对象调研 □分析师会议 □媒体采访 业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 参与单位名称 及人员姓名 参与公司 2024 年度业绩网上说明会活动的投资者 时间 2025 年 5 月 9 日 15:00-17:00 地点 "价值在线"平台（www.ir-online.cn） 上市公司接待 人员姓名 董事长米奇先生 财务总监李福文先生 董事、副总经理、董事会秘书李璐女士 独立董事康立女士 保荐代表人刘彦先生 投资者关系活 动主要内容介 绍 公司于 2025 年 5 月 9 日 15:00-17:00 在"价值在线"（www.ir- online.cn）举办 2024 年度业绩网上说明会，本次业绩说明会采用网络远 程的方式举行，问答环节主要内容如下： 1、问：过去一年，公司的经营策略是什么？ 回复：尊敬的投资者，您好！过去一年，公司董事会管理层确定的经 营策略主要可以用"稳份额、保现金、推注册、剥资产"十二字概括，在 董事会的领导下，公司在生产端严 ...

Core Insights - The article highlights the significant potential of AI in the healthcare sector, particularly in remote medical services and diagnostics, with a focus on the acquisition of Shanghai Siwei Medical Technology Co., Ltd. by Jingtai Holdings for 250 million yuan [1][2][3] Company Summary - Jingtai Holdings has acquired 90% of Shanghai Siwei Medical, the largest remote ECG diagnostic service provider in China, to enhance its AI healthcare business and support drug development [1][2] - The acquisition will enable Jingtai to integrate clinical, molecular, and imaging data to develop precise and efficient remote diagnostic tools for cardiovascular diseases [2][6] - Jingtai aims to leverage Siwei's extensive structured ECG data and clinical experience to create a high-efficiency remote medical and AI-assisted diagnostic platform [6][7] Industry Summary - Cardiovascular diseases are the leading cause of death in China, accounting for over 45% of total deaths, with a significant market for ECG monitoring, estimated at 21 billion yuan [3][4] - The remote ECG testing market is projected to reach 10 billion yuan by 2022, driven by the increasing demand for advanced healthcare solutions amid a shortage of specialized medical professionals [3][4] - Government policies, such as the "Healthy China 2030" initiative, are promoting the integration of AI in healthcare, encouraging the development of remote medical services [4][5]

Core Viewpoint - Insilico Medicine, an AI pharmaceutical company, has submitted its IPO application for the third time after previous attempts failed, indicating a prolonged journey of nearly two years towards going public [1] Group 1: Business Overview - Insilico Medicine operates in three main segments: drug discovery and pipeline development, software solutions, and other discoveries related to non-pharmaceutical fields [2] - The company utilizes its generative AI platform, Pharma.AI, to discover new drug targets related to diseases and to identify promising drug candidates for further development [2] - Currently, the company's drug candidates have not yet been commercialized, with revenue primarily generated from licensing agreements for three candidate drugs [2] Group 2: Financial Performance - Insilico Medicine's revenue for the years 2022 to 2024 was approximately $30.15 million, $51.18 million, and $85.83 million, respectively [3] - The company's net losses for the same years were approximately $222 million, $212 million, and $17 million, respectively [3] Group 3: Funding and Investment - The AI pharmaceutical sector is rapidly evolving, with Insilico Medicine completing multiple funding rounds since its establishment in 2014, attracting notable venture capital and industry investors [4] - The latest funding round, an E round, raised $110 million, led by Hillhouse Capital and involving several prominent investors [4] - The funds raised will accelerate the development of the company's drug pipeline and AI platform [4] Group 4: Industry Context - In 2024, global financing for AI-driven drug development reached $5.8 billion across 128 deals, highlighting the industry's attractiveness to investors despite the lack of profitable standalone AI pharmaceutical companies [5]